295 related articles for article (PubMed ID: 25752998)
21. The topoisomerase I poison CPT-11 enhances the effect of the aurora B kinase inhibitor AZD1152 both in vitro and in vivo.
Nair JS; de Stanchina E; Schwartz GK
Clin Cancer Res; 2009 Mar; 15(6):2022-30. PubMed ID: 19276280
[TBL] [Abstract][Full Text] [Related]
22. Sequential treatment with aurora B inhibitors enhances cisplatin-mediated apoptosis via c-Myc.
Ma Y; Cao H; Lou S; Shao X; Lv W; Qi X; Liu Y; Ying M; He Q; Yang X
J Mol Med (Berl); 2015 Apr; 93(4):427-38. PubMed ID: 25411027
[TBL] [Abstract][Full Text] [Related]
23. Mechanism of action and therapeutic efficacy of Aurora kinase B inhibition in MYC overexpressing medulloblastoma.
Diaz RJ; Golbourn B; Faria C; Picard D; Shih D; Raynaud D; Leadly M; MacKenzie D; Bryant M; Bebenek M; Smith CA; Taylor MD; Huang A; Rutka JT
Oncotarget; 2015 Feb; 6(5):3359-74. PubMed ID: 25739120
[TBL] [Abstract][Full Text] [Related]
24. AZD1152, a novel and selective aurora B kinase inhibitor, induces growth arrest, apoptosis, and sensitization for tubulin depolymerizing agent or topoisomerase II inhibitor in human acute leukemia cells in vitro and in vivo.
Yang J; Ikezoe T; Nishioka C; Tasaka T; Taniguchi A; Kuwayama Y; Komatsu N; Bandobashi K; Togitani K; Koeffler HP; Taguchi H; Yokoyama A
Blood; 2007 Sep; 110(6):2034-40. PubMed ID: 17495131
[TBL] [Abstract][Full Text] [Related]
25. Aurora B kinase inhibitor AZD1152: determinants of action and ability to enhance chemotherapeutics effectiveness in pancreatic and colon cancer.
Azzariti A; Bocci G; Porcelli L; Fioravanti A; Sini P; Simone GM; Quatrale AE; Chiarappa P; Mangia A; Sebastian S; Del Bufalo D; Del Tacca M; Paradiso A
Br J Cancer; 2011 Mar; 104(5):769-80. PubMed ID: 21304529
[TBL] [Abstract][Full Text] [Related]
26. Barasertib (AZD1152), a Small Molecule Aurora B Inhibitor, Inhibits the Growth of SCLC Cell Lines In Vitro and In Vivo.
Helfrich BA; Kim J; Gao D; Chan DC; Zhang Z; Tan AC; Bunn PA
Mol Cancer Ther; 2016 Oct; 15(10):2314-2322. PubMed ID: 27496133
[TBL] [Abstract][Full Text] [Related]
27. Effects of AZD1152, a selective Aurora B kinase inhibitor, on Burkitt's and Hodgkin's lymphomas.
Mori N; Ishikawa C; Senba M; Kimura M; Okano Y
Biochem Pharmacol; 2011 May; 81(9):1106-15. PubMed ID: 21371446
[TBL] [Abstract][Full Text] [Related]
28. Aurora kinase B is important for antiestrogen resistant cell growth and a potential biomarker for tamoxifen resistant breast cancer.
Larsen SL; Yde CW; Laenkholm AV; Rasmussen BB; Duun-Henriksen AK; Bak M; Lykkesfeldt AE; Kirkegaard T
BMC Cancer; 2015 Apr; 15():239. PubMed ID: 25885472
[TBL] [Abstract][Full Text] [Related]
29. Therapeutic polymeric nanoparticles and the methods of making and using thereof: a patent evaluation of WO2015036792.
Sarvagalla S; Hsieh HP; Coumar MS
Expert Opin Ther Pat; 2016 Jul; 26(7):751-5. PubMed ID: 27167102
[TBL] [Abstract][Full Text] [Related]
30. Aurora kinase inhibitor AZD1152 has an additional effect of platinum on a sequential application at the human ovarian cancer cell line SKOV3.
Ma Y; Weimer J; Fredrik R; Adam-Klages S; Sebens S; Caliebe A; Hilpert F; Eckmann-Scholz C; Arnold N; Schem C
Arch Gynecol Obstet; 2013 Jul; 288(1):173-82. PubMed ID: 23389245
[TBL] [Abstract][Full Text] [Related]
31. Selective inhibitors of aurora kinases inhibit proliferation, reduce cell viability and impair cell cycle progression in papillary thyroid carcinoma cells.
Baldini E; Tuccilli C; Prinzi N; Sorrenti S; Antonelli A; Fallahi P; Mian C; Barollo S; Catania A; Morrone S; Tartaglia F; Mascagni D; Coccaro C; Pepe M; Filippini A; D'Armiento M; Ulisse S
J Biol Regul Homeost Agents; 2015; 29(4):793-803. PubMed ID: 26753639
[TBL] [Abstract][Full Text] [Related]
32. Effect of the drug transporters ABCG2, Abcg2, ABCB1 and ABCC2 on the disposition, brain accumulation and myelotoxicity of the aurora kinase B inhibitor barasertib and its more active form barasertib-hydroxy-QPA.
Marchetti S; Pluim D; van Eijndhoven M; van Tellingen O; Mazzanti R; Beijnen JH; Schellens JH
Invest New Drugs; 2013 Oct; 31(5):1125-35. PubMed ID: 23315030
[TBL] [Abstract][Full Text] [Related]
33. AURKB as a target in non-small cell lung cancer with acquired resistance to anti-EGFR therapy.
Bertran-Alamillo J; Cattan V; Schoumacher M; Codony-Servat J; Giménez-Capitán A; Cantero F; Burbridge M; Rodríguez S; Teixidó C; Roman R; Castellví J; García-Román S; Codony-Servat C; Viteri S; Cardona AF; Karachaliou N; Rosell R; Molina-Vila MA
Nat Commun; 2019 Apr; 10(1):1812. PubMed ID: 31000705
[TBL] [Abstract][Full Text] [Related]
34. Clinical evaluation of AZD1152, an i.v. inhibitor of Aurora B kinase, in patients with solid malignant tumors.
Boss DS; Witteveen PO; van der Sar J; Lolkema MP; Voest EE; Stockman PK; Ataman O; Wilson D; Das S; Schellens JH
Ann Oncol; 2011 Feb; 22(2):431-7. PubMed ID: 20924078
[TBL] [Abstract][Full Text] [Related]
35. Optimizing Therapeutic Effect of Aurora B Inhibition in Acute Myeloid Leukemia with AZD2811 Nanoparticles.
Floc'h N; Ashton S; Taylor P; Trueman D; Harris E; Odedra R; Maratea K; Derbyshire N; Caddy J; Jacobs VN; Hattersley M; Wen S; Curtis NJ; Pilling JE; Pease EJ; Barry ST
Mol Cancer Ther; 2017 Jun; 16(6):1031-1040. PubMed ID: 28292940
[TBL] [Abstract][Full Text] [Related]
36. AZD1152 rapidly and negatively affects the growth and survival of human acute myeloid leukemia cells in vitro and in vivo.
Oke A; Pearce D; Wilkinson RW; Crafter C; Odedra R; Cavenagh J; Fitzgibbon J; Lister AT; Joel S; Bonnet D
Cancer Res; 2009 May; 69(10):4150-8. PubMed ID: 19366807
[TBL] [Abstract][Full Text] [Related]
37. Aurora B kinase regulates the postmitotic endoreduplication checkpoint via phosphorylation of the retinoblastoma protein at serine 780.
Nair JS; Ho AL; Tse AN; Coward J; Cheema H; Ambrosini G; Keen N; Schwartz GK
Mol Biol Cell; 2009 Apr; 20(8):2218-28. PubMed ID: 19225156
[TBL] [Abstract][Full Text] [Related]
38. Hypersensitivity to aurora kinase inhibitors in cells resistant against platinum- containing anticancer agents.
Akiyama M; Izumi H; Wang KY; Yamaguchi T; Kuma A; Kitamura N; Harada Y; Oya R; Yamaguchi K; Iwai Y; Kohno K
Anticancer Agents Med Chem; 2014; 14(7):1042-50. PubMed ID: 24521151
[TBL] [Abstract][Full Text] [Related]
39. The selective Aurora B kinase inhibitor AZD1152 as a novel treatment for hepatocellular carcinoma.
Aihara A; Tanaka S; Yasen M; Matsumura S; Mitsunori Y; Murakata A; Noguchi N; Kudo A; Nakamura N; Ito K; Arii S
J Hepatol; 2010 Jan; 52(1):63-71. PubMed ID: 19913935
[TBL] [Abstract][Full Text] [Related]
40. Aurora kinase B/C inhibition impairs malignant glioma growth in vivo.
Diaz RJ; Golbourn B; Shekarforoush M; Smith CA; Rutka JT
J Neurooncol; 2012 Jul; 108(3):349-60. PubMed ID: 22382783
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
